Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, according to findings published in Blood Advances.Results showed the agent ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these ...

One of the most severe manifestations of COVID-19 is Acute Respiratory Distress Syndrome (ARDS), a life ... inflammatory response known as a ‘cytokine storm’ that causes ARDS and damage ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

What are cytokines? “Simply put, cytokines are small proteins which tell the immune cells ... The patient can also get acute respiratory distress syndrome (ARDS). Heart: The immune system attacks the ...

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

What are cytokines? “Simply put ... The patient can also get acute respiratory distress syndrome (ARDS). Heart: The immune system attacks the heart muscles, causing tachycardia, where the ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...